Leading Diagnosis and Management of Multiple Sclerosis

Dear Colleagues,

Diagnostics has launched a Special Issue entitled “Leading Diagnosis and Management of Multiple Sclerosis”.

In the past 15 years, we have entered a new era of multiple sclerosis treatment. Since 2011, three new diagnostic criteria systems have been created to make the diagnosis of MS faster and easier; in 2014, a new phenotypic classification was published; in 2017, the first ever international consensus therapeutic guideline was implemented; and in 2019, the criteria of the MS center was created for the first time. Nowadays, more than 15 disease-modifying therapies are utilized for all clinical courses, making the management of even the most aggressive cases possible.

However, with new knowledge, new questions always arise. We still lack any validated reliable biomarker for either the activity, the progression or the prognosis of the disease. We still cannot predict the effect of disease-modifying treatments at initiation, and many DMTs still lack long-term real-world data on effectivity. Additionally, the less commonly measured, yet highly debilitating symptoms of the disease—cognitive impairment, fatigue and mood disorders—are still underdiagnosed and undertreated despite their grave effect on patients’ quality of life and overall progression.

Therefore, we wholeheartedly invite global practitioners and investigators to submit original research articles or review articles to this Special Issue. The scope of the Issue includes, but is not limited to:

• The diagnosis, follow-up and management of pathopsychological symptoms (cognitive impairment, fatigue, depression and anxiety) of multiple sclerosis;
• Real-world data on the long-term management of disease-modifying therapies;
• Molecular, imaging or clinical biomarkers for the diagnosis, differential diagnosis, disease activity, progression and therapeutic follow-up of multiple sclerosis;
• The challenges of differential diagnosis in cases of multiple sclerosis.

Dr. Dániel Sandi
Dr. Krisztina Bencsik
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• multiple sclerosis
• cognition
• mood disorders
• disease-modifying therapies
• biomarkers